Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21840558 | 0.78 | CYP2C19 (0.44) | GRM5CYP2C19CYP2C9KMT2AHPGD | |
| SCHEMBL27893222 | 0.77 | HCAR2 (0.40) | KMT2AALDH1A1CA12CA9KDM4E | |
| SCHEMBL17331633 | 0.77 | KDM4E (0.55) | GRM5KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL16739572 | 0.77 | ALDH1A1 (0.49) | GRM5CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL14457454 | 0.75 | HPGD (0.44) | GRM5ALDH1A1HPGDCA12CA1 | |
| SCHEMBL19389556 | 0.75 | CYP2C9 (0.48) | GRM5CYP2C19CYP2C9KMT2AALDH1A1 | |
| SCHEMBL29308627 | 0.74 | CHRNA7 (0.44) | GRM5ALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL17331567 | 0.74 | GRM5 (0.47) | GRM5KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL19389555 | 0.74 | CA12 (0.45) | ALDH1A1HPGDCA12CA1CA2 | |
| SCHEMBL27760005 | 0.74 | MAP4K4 (0.51) | GRM5CYP2C19CYP2C9KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | GRM5 1304/4885CYP2C19 4392/4885CYP2C9 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.